MEDI 534

Drug Profile

MEDI 534

Alternative Names: MEDI-534; Parainfluenza/respiratory syncytial virus vaccine - MedImmune; RSV/PIV-3 vaccine - MedImmune

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator MedImmune
  • Class Respiratory syncytial virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Parainfluenza virus infections; Respiratory syncytial virus infections

Most Recent Events

  • 30 Jun 2012 Discontinued - Phase-I/II for Parainfluenza virus infections in Australia (Intranasal)
  • 30 Jun 2012 Discontinued - Phase-I/II for Parainfluenza virus infections in Brazil (Intranasal)
  • 30 Jun 2012 Discontinued - Phase-I/II for Parainfluenza virus infections in Canada (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top